Sofinnova Partners, a premier European venture capital firm specializing in life sciences, has announced the successful closing of its Sofinnova Digital Medicine I fund at an impressive $200 million (€190M). This significant achievement surpasses the initial target, highlighting strong investor confidence in Sofinnova Partners’ vision and expertise in the burgeoning digital medicine sector. Based in Paris, London, and Milan, Sofinnova Partners is strategically positioned to foster innovation at the intersection of biology, data, and computation. The Digital Medicine I fund, led by Partners Edward Kliphuis and Simon Turner, will focus on supporting visionary entrepreneurs who are driving this convergence and shaping the future of healthcare.
Sofinnova Partners’ Commitment to Digital Health Innovation
Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, emphasized the firm’s dedication to pioneering advancements in life sciences: “The oversubscribed closing of Sofinnova Digital Medicine I underscores Sofinnova Partners’ ongoing expansion as a global leader in nurturing groundbreaking innovations within the life sciences arena. This latest fund within our diverse investment strategies portfolio demonstrates the unwavering confidence our limited partners have in our strategic direction and Sofinnova’s enduring commitment to spearheading the evolution of healthcare.”
The Sofinnova Digital Medicine strategy arrives at a crucial juncture in the healthcare industry, where digital technologies are catalyzing transformative changes. Sofinnova Partners recognizes this pivotal moment and is strategically deploying capital to support the digital revolution in healthcare. The fund is strategically focused on three core pillars:
- Enabling Technologies: Investing in the foundational technologies that power digital medicine advancements.
- Analytics: Supporting companies leveraging data and AI to derive actionable insights for improved healthcare outcomes.
- Treatment: Backing innovative digital therapeutics and solutions that directly enhance patient care and treatment paradigms.
By providing not only crucial financial resources but also deep industry expertise and an extensive network within the healthcare ecosystem, Sofinnova Partners empowers entrepreneurs to effectively tackle global healthcare challenges and deliver tangible improvements in patient outcomes worldwide.
Early Investments Showcase Sofinnova Partners’ Strategic Direction
Sofinnova Digital Medicine I has already made strategic investments in five high-potential companies, demonstrating the fund’s rapid deployment and commitment to identifying and supporting leading innovators. Among the recent additions to the Sofinnova Digital Medicine portfolio are:
- L’école AI: This innovative company, founded by a former key member of Twitter’s Cortex team, has developed groundbreaking “machine teaching” technology. This technology simplifies the implementation of deep-learning systems for computer vision applications within the life sciences, significantly reducing barriers to entry and accelerating innovation.
- Betteromics: Recognizing the critical need for data integration in the omics space, Betteromics has created the “Omics AI Cloud.” This certified SaaS platform unifies disparate health and omics data into a centralized, reliable source of truth. The company’s founding team brings deep expertise from leading organizations such as GRAIL, Verily, and Google’s Search Knowledge Graph, ensuring a robust and cutting-edge approach to data management and analysis.
Edward Kliphuis, Partner at Sofinnova Partners, highlights the fund’s early momentum and strategic focus: “Within just a few months of launching this strategy, Sofinnova Partners has already invested in five transformative companies, including Kiro, BioCorteX, deepc, L’école AI, and Betteromics. These companies are at the forefront of merging advanced computational methods with cutting-edge biological innovations. Leveraging Sofinnova’s extensive expertise and network, we act as strategic allies to digital medicine pioneers, enabling them to achieve product-market fit and scale effectively on a global scale.”
Simon Turner, Partner at Sofinnova Partners, further elaborates on the firm’s value proposition to portfolio companies: “Sofinnova Partners brings its profound healthcare domain knowledge to entrepreneurs who are pioneering at the cutting edge of digital medicine. We understand the unique challenges and opportunities where biology converges with tech-industry best practices such as rapid product iteration and accelerated commercialization. Our primary objective is to champion innovators who are developing disruptive solutions that will significantly benefit both patients and healthcare systems.”
About Sofinnova Partners: A Leader in European Life Sciences Venture Capital
Sofinnova Partners stands as a preeminent European venture capital firm dedicated to life sciences, with a dual focus on healthcare and sustainability. With offices strategically located in Paris, London, and Milan, Sofinnova Partners boasts a global team of seasoned professionals with deep scientific, medical, and business acumen. Sofinnova Partners adopts a hands-on approach to company building across the entire spectrum of life sciences investments, from seed-stage ventures to later-stage growth companies. The firm actively collaborates with ambitious entrepreneurs, often serving as a lead or cornerstone investor, to cultivate transformative innovations with the potential to generate a positive and lasting impact on our collective future.
Established in 1972, Sofinnova Partners has cultivated a rich heritage as a deeply rooted venture capital institution in Europe. Over five decades, the firm has backed more than 500 companies, playing a pivotal role in creating market-leading organizations across the globe. Currently, Sofinnova Partners manages over €2.5 billion in assets.
For further information about Sofinnova Partners and its activities, please visit: sofinnovapartners.com.
Contacts
Bommy Lee
Head of Communications
Sofinnova Partners
[email protected]
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
[email protected]
+1 212 223 0561
United Kingdom
Optimum Strategic Communications
Hana Malik
[email protected]
+44 (0) 20 3922 0900
France
StrategiesImage
Anne Rein
[email protected]
+33 (0) 6 03 35 92 05
Italy
Havas PR Milan
Pierluigi Cavarai
[email protected]
+39 (0) 392 77 999 33
